Securities code: 300138 securities abbreviation: Chenguang Biotech Group Co.Ltd(300138) Announcement No.: 2021-163 Chenguang Biotech Group Co.Ltd(300138)
Announcement on capital increase to subsidiary Chenguang pharmaceutical
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
1、 Overview
The 37th meeting of the Fourth Board of directors of Chenguang Biotech Group Co.Ltd(300138) (hereinafter referred to as “the company”) deliberated and adopted the proposal on capital increase to Chenguang pharmaceutical, a subsidiary , in order to meet its business needs, improve its asset liability structure and consider its investment in Tianrun pharmaceutical, the company decided to use its own funds to increase the capital of Chenguang Pharmaceutical by 81 million yuan. After the capital increase, the registered capital of Chenguang pharmaceutical will increase to 100 million yuan.
This capital increase to the subsidiary does not constitute a related party transaction, nor does it constitute a major asset reorganization specified in the administrative measures for major asset reorganization of listed companies. Within the approval authority of the company’s board of directors, it is not necessary to submit it to the general meeting of shareholders for deliberation.
2、 Basic information of Chenguang pharmaceutical industry
1. Capital increase method: the company decided to use its own capital of 81 million yuan to increase capital to Chenguang pharmaceutical.
2. Basic information of Chenguang pharmaceutical industry
Company name: Hebei Chenguang Pharmaceutical Co., Ltd
Address: No. 9, maosui street, Handan Economic Development Zone, Hebei Province
Enterprise type: limited liability company
Legal representative: Wan Haichao
Registered capital: 19 million yuan
Business scope: production and sales of tablets, hard capsules, granules and pills (honey pills); drug technology research and development, technology transfer and technical consultation; drug sales (operating with drug business license); cultivation of Chinese herbal medicine (excluding original medicinal plants of narcotic drugs).
Chenguang pharmaceutical is a wholly-owned subsidiary of the company. After the capital increase, the registered capital of Chenguang pharmaceutical will increase to 100 million yuan.
The main financial data of Chenguang pharmaceutical in the latest year are as follows:
Project on November 30, 2021 or December 31, 2020 or
January November 2021 January December 2020
Total assets (10000 yuan) 4061.013235.13
Total liabilities (10000 yuan) 2519.201452.02
Owner’s equity (10000 yuan) 1541811783.11
Operating income (10000 yuan) 648-
Total profit (10000 yuan) -241.30-108.13
Net profit (10000 yuan) -241.30-108.13
3、 Purpose of capital increase to subsidiaries, existing risks and impact on the company
The third step of the company’s “three-step” development strategy is to expand and strengthen major health industries such as health products and traditional Chinese medicine extraction, so as to contribute to human health.
Chenguang pharmaceutical undertakes the development of traditional Chinese medicine business and directly holds the equity of Tianrun pharmaceutical. The subsidiary is still in the preparatory period. As of the end of November, the registered capital was 19 million yuan, The amount of non current assets is 38.53 million yuan (fixed assets and investment in Tianrun pharmaceutical). In order to meet its business needs, improve the asset liability structure and consider its investment in Tianrun pharmaceutical, the company plans to use its own funds to increase the capital of Chenguang Pharmaceutical by 81 million yuan. After the capital increase, the registered capital of Chenguang pharmaceutical will increase to 100 million yuan.
Chenguang pharmaceutical is a wholly-owned subsidiary of the company. After the capital increase, the scope of consolidated statements will not be changed and will not have an impact on the company’s financial situation. Subsequently, the company will issue a progress announcement according to the progress of capital increase.
4、 Documents for future reference
1. Resolution of the 37th meeting of the 4th board of directors
2. Basic data of Chenguang pharmaceutical industry
It is hereby announced
Chenguang Biotech Group Co.Ltd(300138) board of directors
December 26, 2021
